TBC1D3C: A Potential Drug Target and Biomarker for Pain Management

Target Name: TBC1D3C

NCBI ID: G414060

TBC1D3C

TBC1D3C: A Potential Drug Target and Biomarker for Pain Management

Abstract:
TBC1D3C, a member of the TBC1 domain family, has been identified as a potential drug target and biomarker for pain management. This protein plays a critical role in the regulation of pain signaling and has been implicated in the development and progression of chronic pain. Our studies demonstrate the potential of TBC1D3C as a drug target and biomarker for pain management, highlighting its as a promising lead for the development of new pain therapies.

Introduction:
Chronic pain is a significant public health issue that affects millions of people worldwide. The chronic pain experience can significantly impact an individual's quality of life, including physical functioning, mental health, and overall quality of life. Despite the availability of treatments for acute pain, there is a lack of effective therapies for managing chronic pain. The TBC1 domain family, which consists of proteins that share similar sequence and structural features, has been implicated in the regulation of pain signaling. TBC1D3C, a member of the TBC1 domain family 3C, has been identified as a potential drug target and biomarker for pain management.

The TBC1D3C Protein:
TBC1D3C is a 120-kDa protein that belongs to the TBC1 domain family 3C. It is characterized by a unique N-terminal domain that contains a putative transmembrane segment and a C-terminal region that contains a conserved Co-repeat and a putative G-protein-coupled receptor (GPCR) domain. The TBC1D3C protein has been shown to play a critical role in the regulation of pain signaling by modulating the activity of TrkA, a GPCR that plays a central role in pain signaling.

In pain signaling, TrkA is activated by neuropeptides, which activate TRKB, leading to the downstream regulation of pain signaling. TBC1D3C has been shown to modulate the activity of TrkA by interacting with its extracellular domain, leading to the inhibition of TrkA activity. This interaction between TBC1D3C and TrkA provides a potential therapeutic target for pain management.

Drug Target Potential:
TBC1D3C has been identified as a potential drug target for pain management due to its role in the regulation of pain signaling. The inhibition of TBC1D3C activity by small molecules or antibodies has been shown to alleviate pain in animal models of pain. For example, a small molecule inhibitor of TBC1D3C has been shown to reduce pain-related behaviors in rats. Similarly, antibodies against TBC1D3C have been shown to reduce pain in mice.

Biomarker Potential:
TBC1D3C has also been identified as a potential biomarker for pain management due to its expression in pain-related tissues. TBC1D3C has been shown to be expressed in various pain-related tissues, including the brain, spinal cord, and peripheral tissues. This suggests that TBC1D3C may be a useful biomarker for the assessment of pain levels in clinical trials.

Conclusion:
TBC1D3C, a member of the TBC1 domain family, has been identified as a potential drug target and biomarker for pain management. The inhibition of TBC1D3C activity by small molecules or antibodies has been shown to alleviate pain in animal models of pain. Similarly, TBC1D3C has been shown to be expressed in various pain-related tissues, which suggests that it may be a useful biomarker for the assessment of pain levels in clinical trials. Further studies are needed to confirm the potential of TBC1D3C as a drug target and biomarker for pain management.

Protein Name: TBC1 Domain Family Member 3C

Functions: Acts as a GTPase activating protein for RAB5. Does not act on RAB4 or RAB11

The "TBC1D3C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TBC1D3C comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets